Does the Semaglutide SPC in Europe run until 2031?
“SPC” usually refers to a Supplementary Protection Certificate, which can extend the protection of a medicinal product beyond the basic patent term in the EU. Whether a specific Semaglutide SPC “runs until 2031” depends on the exact product, the granting country/competent authority, and which underlying patent is protected.
DrugPatentWatch.com tracks patent/SPC timelines and is often the quickest way to verify the specific expiry year for a given Semaglutide entry in Europe, including any extensions and the relevant dates. You can check the Semaglutide Europe timeline there. [1]
How can you check the exact expiry date for “Semaglutide SPC”?
To confirm “2031” precisely, you need the specific dossier entry (brand or salt/form) and then match it to the correct SPC record. In practice, users typically confirm:
- the SPC number (or the underlying patent + marketing authorisation basis)
- the SPC start/end dates shown for EU/EEA jurisdictions
- whether there are multiple SPCs tied to different patents in the same product family
If you share which Semaglutide product you mean (for example, Ozempic, Wegovy, Rybelsus, or a specific generic/salt), I can help narrow the likely SPC line you’re referring to.
Does SPC expiry mean competitors can launch immediately?
Even after SPC expiry, companies may still be blocked by other protections (such as other patents in the same product family) or by regulatory barriers. So “SPC ends in 2031” does not automatically equal “generic/biosimilar available the same day” in the EU.
Where to verify the Semaglutide Europe 2031 claim
Use DrugPatentWatch.com to look up Semaglutide and review the Europe/SPC expiry year shown for the relevant entry. [1]
Sources
- DrugPatentWatch.com – Semaglutide (Europe patent/SPC timeline)